[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606508":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":26,"locations":36,"responsibleParty":69,"collaborators":18,"id":72,"slug":18,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":18,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Anhui Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental:Neuronavigation-guided individualized intermittent theta burst stimulation (iTBS)","EXPERIMENTAL","Participants will receive iTBS daily for 2 week within real-world treatment settings",[13],"Other: Neuronavigation-guided individualized iTBS",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group: ordinary drug treatment","NO_INTERVENTION","The participants will receive regular medication treatment every day for 2 week.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Neuronavigation-guided individualized iTBS","Participants will receive individualized iTBS for 14 consecutive days in addition to their usual medication regimen.\n\niTBS parameters: 50 Hz bursts every 200 ms (5 Hz), 2s on\u002F8s off, total 600 pulses per session;6 sessions\u002Fday (3 in morning, 3 in afternoon, 3600 pulses\u002Fday); 100% RMT intensity; Neuronavigation: Brainsight system (Rogue Research, Canada)",[9],[25],"iTBS",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":18,"email":31},"Kai Wang, MD","CONTACT","0551 6516 7581","wangkai1964@126.com",{"name":33,"role":29,"phone":34,"phoneExt":18,"email":35},"Gong-Jun Ji, PhD","+8618134516380","jigongjun@163.com",[37,55],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Hefei","Anhui","230000","China","CN",{"type":45,"coordinates":46},"Point",[47,48],117.28083,31.86389,{"lat":48,"lon":47},[51],{"name":52,"role":29,"phone":53,"phoneExt":18,"email":54},"Gong-Jun Ji","+86-18134516380","2015500024@ahmu.edu.cn",{"facility":5,"status":56,"city":39,"state":40,"zip":57,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":60,"contacts":61},"NOT_YET_RECRUITING","230032",{"type":45,"coordinates":59},[47,48],{"lat":48,"lon":47},[62,64,66],{"name":63,"role":29,"phone":30,"phoneExt":18,"email":31},"Kai Wang, PhD",{"name":65,"role":29,"phone":34,"phoneExt":18,"email":35},"Gong-Jun, PhD",{"name":67,"role":68,"phone":18,"phoneExt":18,"email":18},"Qiang Hua, PhD","PRINCIPAL_INVESTIGATOR",{"type":68,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"WANG KAI","Head of the Department, Department of Neurology, The First Affiliated Hospital of Anhui Medical University","100606508",false,"NCT07176468","Personalized iTBS in Real-World Clinical Settings for Schizophrenia","Efficacy of Personalized iTBS in Real-World Clinical Settings for Alleviating Schizophrenia Symptoms : A Randomized Single-Blind Trial","EPSREAL-SC","Inclusion Criteria:\n\n* Aged 18-60 years, any gender\n* Meets DSM-5 criteria for schizophrenia\n* Antipsychotic medication change (initiation, dose adjustment, or switch) occurred within the past 3 days\n* Capable of understanding the study and providing written informed consent Able to comply with study procedures and complete assessments\n\nExclusion Criteria:\n\n* Active suicidal ideation or behavior\n* Major neurological disorders (e.g., epilepsy, organic brain lesions, severe head trauma)\n* Contraindications to MRI or TMS (e.g., metal implants, pacemakers)\n* Pregnancy or lactation\n* Receipt of TMS or ECT within the past 6 months\n* Judged by investigators to be unsuitable for participation","ALL","18 Years","60 Years",{"count":83,"type":84},40,"ESTIMATED","INTERVENTIONAL",[87],"NA","This study is designed to determine whether neuronavigation-guided, personalized Intermittent Theta-Burst Stimulation (iTBS) can produce clinically benefits for patients with schizophrenia when delivered in real-world treatment settings. By situating the intervention within real-world treatment settings-without imposing restrictions on concurrent pharmacotherapy-this trial seeks to generate evidence that is both scientifically rigorous and clinically relevant.\n\nThe main questions it seeks to address are:\n\nDoes the personalized iTBS target TMS protocol improve clinical symptoms in patients with schizophrenia within real-world treatment settings? What neural circuit changes, as assessed by functional MRI, occur following TMS treatment?\n\nParticipants will:\n\nUndergo personalized,personalized iTBS target treatment daily for 2 weeks. Complete baseline and post-treatment assessments, including clinical symptom scales (PANSS, HAMA, HAMD) and neuropsychological tests (MoCA, DST, VFT, Stroop Test, and AVLT).\n\nHave structural and resting-state functional MRI scans before and after treatment.\n\nBe monitored for any treatment-related adverse events.",[90,91],"Schizophrenia","Transcranial Magnetic Stimulation",[93,94,95],"schizophrenia","transcranial magnetic stimulation","Functional Magnetic Resonance Imaging (fMRI)","2025-12-28",{"date":98,"type":99},"2025-12-30","ACTUAL",{"date":101,"type":99},"2025-10-20",{"date":103,"type":84},"2026-09-20",{"name":5,"class":6},2]